Verrica Pharmaceuticals Inc.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $35.6M
- Net income
- -$17.9M
- Total assets
- $47.1M
- Market cap
- $103.8M
- Operating margin
- -34.2%
- Net margin
- -50.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $35.6M
- Operating expenses
- $47.8M
- Operating income
- -$12.2M
- Income tax
- $0
- Net income
- -$17.9M
- EPS (basic)
- $-1.68
- EPS (diluted)
- $-1.68
Balance sheet
- Total assets
- $47.1M
- Current assets
- $42.5M
- Total liabilities
- $22.4M
- Current liabilities
- $16.4M
- Shareholders’ equity
- $24.7M
Cash flow
- Operating cash flow
- -$17.6M
- Investing cash flow
- $16.2M
- Financing cash flow
- $1.4M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $103.8M
- EPS (diluted)
- $-1.68
- Shares outstanding
- 17.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 15, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $17.9M in FY2025.
- Revenue grew 196% from FY2021 to FY2025.
- Trading 34% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Verrica Pharmaceuticals Inc..
Write a review
News about Verrica Pharmaceuticals Inc.
News & sentiment via Polygon.io
